Can-Fite BioPharma Ltd.CANFNYSE
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank41
Year-over-Year Change
Year-over-year SG&A expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P41
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
3.95%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | 35.74% |
| Q4 2024 | 0.00% |
| Q3 2024 | -0.20% |
| Q2 2024 | 0.00% |
| Q1 2024 | 5.61% |
| Q4 2023 | -5.25% |
| Q3 2023 | 22.12% |
| Q2 2023 | -26.33% |
| Q1 2023 | 2.54% |
| Q4 2022 | 11.47% |
| Q3 2022 | -9.85% |
| Q2 2022 | 9.02% |
| Q1 2022 | -33.33% |
| Q4 2021 | 37.59% |
| Q3 2021 | -6.16% |
| Q2 2021 | -13.78% |
| Q1 2021 | 25.90% |
| Q4 2020 | 17.13% |
| Q3 2020 | -8.38% |
| Q2 2020 | 6.97% |
| Q1 2020 | -3.96% |
| Q4 2019 | -17.47% |
| Q3 2019 | 15.80% |
| Q2 2019 | 35.10% |
| Q1 2019 | -14.61% |
| Q4 2018 | 17.11% |
| Q3 2018 | -37.83% |
| Q2 2018 | 0.55% |
| Q1 2018 | 13.61% |
| Q4 2017 | 15.53% |
| Q3 2017 | 6.15% |
| Q2 2017 | -16.27% |
| Q1 2017 | 29.99% |
| Q4 2016 | -25.48% |
| Q3 2016 | 19.73% |
| Q2 2016 | 7.21% |
| Q1 2016 | -35.60% |
| Q4 2015 | 96.80% |
| Q3 2015 | -19.09% |